Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment

E. Lahner, C. Bordi, E. Di Giulio, P. Caruana, G. D'Ambra, M. Milione, C. Grossi, G. Delle Fave, B. Annibale

Research output: Contribution to journalArticle

Abstract

Background: It has been reported that 50% of patients with atrophic body gastritis have positive Helicobacter pylori antibody titres only. In atrophic body gastritis, a decrease in H. pylori antibodies after eradication treatment has been reported, suggesting that serology may indicate an active H. pylori infection. Aim: To investigate the time course of H. pylori antibodies and gastric inflammation after eradication treatment in patients with atrophic body gastritis, and to determine whether serology alone can be considered as a valid tool to assess the efficacy of eradication treatment in patients with atrophic body gastritis. Methods: Twenty-seven patients with atrophic body gastritis (12 serologically H. pylori-positive only, ABG-S+; 15 H. pylori-positive at histology and serology, ABG-H+) were included in the treatment group, and 17 patients (all ABG-S+) in the no treatment group. All patients had gastroscopy plus biopsies evaluated according to the updated Sydney system and H. pylori immunoglobulin G determination: in the treatment group, at baseline and 6 and 24 months after eradication (bismuth-based triple regimens): in the no treatment group, at baseline and after 3 years. Results: In the treatment group, in ABG-S+ patients, H. pylori antibodies decreased significantly 6 months after treatment [37.5 U/mL (16-100 U/mL) vs. 15 U/mL (0-100 U/mL), P <0.01], but 2 years after treatment no further decrease occurred. In addition, in ABG-H+ patients, a significant decrease in H. pylori antibodies occurred 6 months after treatment [45 U/mL (12.5-100 U/mL) vs. 31 U/mL(0-65 U/mL), P <0.01], but a further decrease was also observed 2 years after treatment [20 U/mL (0-56 U/mL), P <0.01]. In ABG-S+ patients, no correlation was observed between the H. pylori antibodies and gastric inflammation score, whereas, in the ABG-H+ group, this correlation was extremely significant (r = 0.5991, P <0.0001). In the no treatment group, at follow-up, a significant decrease in H. pylori antibodies was observed [26 U/mL (15-100 U/mL) vs. 22 U/mL (0-53 U/mL), P <0.05], but the gastric body inflammation remained unchanged. Conclusions: This study shows that, in ABG-S+ patients after eradication treatment, serology does not keep in step with gastric inflammation. This suggests that, in patients with atrophic body gastritis, serology alone may not be valid for the assessment of the efficacy of eradication treatment.

Original languageEnglish
Pages (from-to)507-514
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number3
DOIs
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment'. Together they form a unique fingerprint.

  • Cite this

    Lahner, E., Bordi, C., Di Giulio, E., Caruana, P., D'Ambra, G., Milione, M., Grossi, C., Delle Fave, G., & Annibale, B. (2002). Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Alimentary Pharmacology and Therapeutics, 16(3), 507-514. https://doi.org/10.1046/j.1365-2036.2002.01213.x